• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Novo Nordisk Dives After FDA Reportedly Finds 'Objectionable' Conditions At A Key...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 18, 2023 at 08:22: PM
via Novo Nordisk (NVO) stock skidded Monday on reports a Food and Drug Administration inspection turned up "objectionable conditions" at a facility charged with making diabetes and weight-loss drugs.

article source
 




Top Bottom
Back
Quote